Drug Trial Radar · NCT01345253
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
Last checked: Nov 20, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
709
Actual
Start
May 23, 2011
Primary completion
Sep 15, 2015
Study completion Sep 21, 2018
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Human Genome Sciences Inc.
- First posted
- May 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus erythematosus (SLE) over a 52 week period.
Conditions
- Systemic Lupus Erythematosus
Interventions
BelimumabDrug
10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
PlaceboDrug
Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase.Time frame: Week 52
Locations
47 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Tianjin, China
GSK Investigational Site
Hefei, Anhui, China
GSK Investigational Site
Guangzhou, Guangdong, China
GSK Investigational Site
Guangzhou, Guangdong, China
GSK Investigational Site
Guangzhou, Guangdong, China
GSK Investigational Site
Harbin, Heilongjiang, China
GSK Investigational Site
Changsha, Hunan, China
GSK Investigational Site
Changsha, Hunan, China
GSK Investigational Site
Nanjing, Jiangsu, China
GSK Investigational Site
Suzhou, Jiangsu, China
GSK Investigational Site
Xi'an, Shaanxi, China
GSK Investigational Site
Jinan, Shandong, China
GSK Investigational Site
Chengdu, Sichuan, China
GSK Investigational Site
Kunming, Yunnan, China
GSK Investigational Site
Hangzhou, Zhejiang, China
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Ehime, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Hiroshima, Japan
GSK Investigational Site
Hiroshima, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hyōgo, Japan
GSK Investigational Site
Miyagi, Japan
GSK Investigational Site
Nagasaki, Japan
GSK Investigational Site
Nagasaki, Japan
GSK Investigational Site
Okayama, Japan
GSK Investigational Site
Okinawa, Japan
GSK Investigational Site
Tochigi, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Busan, South Korea
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.